SG Americas Securities LLC Acquires Shares of 17,261 Enovis Co. (NYSE:ENOV)

SG Americas Securities LLC acquired a new position in Enovis Co. (NYSE:ENOV - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 17,261 shares of the company's stock, valued at approximately $757,000.

Several other large investors also recently added to or reduced their stakes in ENOV. Confluence Investment Management LLC purchased a new stake in shares of Enovis in the 4th quarter valued at about $3,494,000. Chartwell Investment Partners LLC raised its stake in Enovis by 25.6% in the third quarter. Chartwell Investment Partners LLC now owns 201,652 shares of the company's stock valued at $8,681,000 after purchasing an additional 41,089 shares in the last quarter. Geode Capital Management LLC lifted its position in Enovis by 9.5% during the third quarter. Geode Capital Management LLC now owns 921,437 shares of the company's stock valued at $39,678,000 after purchasing an additional 80,165 shares during the last quarter. UMB Bank n.a. grew its stake in Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after buying an additional 437 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Enovis in the 3rd quarter worth $1,050,000. Institutional investors own 98.45% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ENOV. JMP Securities began coverage on shares of Enovis in a research report on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and issued a $65.00 price objective on shares of Enovis in a report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Enovis presently has an average rating of "Moderate Buy" and an average target price of $65.86.

Enovis Trading Up 0.4 %

Shares of NYSE:ENOV traded up $0.19 on Thursday, reaching $47.56. 595,518 shares of the company traded hands, compared to its average volume of 1,288,643. The stock has a market capitalization of $2.66 billion, a P/E ratio of -21.72 and a beta of 1.94. The business's 50-day simple moving average is $46.07 and its 200 day simple moving average is $44.51. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.11. The business had revenue of $505.22 million for the quarter, compared to analyst estimates of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Enovis's revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period last year, the company earned $0.56 EPS. As a group, equities analysts anticipate that Enovis Co. will post 2.79 EPS for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.